MetLife Investment Management’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-59,442
| Closed | -$1.4M | – | 2836 |
|
|
2023
Q4 | $1.4M | Buy |
59,442
+7,640
| +15% | +$136K | 0.01% | 1130 |
|
|
2023
Q3 | $772K | Hold |
51,802
| – | – | 0.01% | 1373 |
|
|
2023
Q2 | $567K | Buy |
+51,802
| New | +$482K | ﹤0.01% | 1614 |
|
|
2022
Q2 | – | Sell |
-52,338
| Closed | -$163K | – | 2923 |
|
|
2022
Q1 | $163K | Buy |
+52,338
| New | +$165K | ﹤0.01% | 2475 |
|
|
2021
Q4 | – | Sell |
-26,489
| Closed | -$96.7K | – | 2568 |
|
|
2021
Q3 | $96.7K | Buy |
+26,489
| New | +$104K | ﹤0.01% | 2455 |
|
|
2021
Q2 | – | Sell |
-31,252
| Closed | -$142K | – | 2504 |
|
|
2021
Q1 | $142K | Buy |
31,252
+15,959
| +104% | +$85.9K | ﹤0.01% | 2206 |
|
|
2020
Q4 | $87.8K | Sell |
15,293
-6,111
| -29% | -$46.3K | ﹤0.01% | 2236 |
|
|
2020
Q3 | $155K | Sell |
21,404
-13,457
| -39% | -$72K | ﹤0.01% | 2010 |
|
|
2020
Q2 | $122K | Buy |
+34,861
| New | +$101K | ﹤0.01% | 2161 |
|
|
2019
Q4 | – | Sell |
-24,969
| Closed | -$128K | – | 2340 |
|
|
2019
Q3 | $128K | Sell |
24,969
-16,881
| -40% | -$102K | ﹤0.01% | 2199 |
|
|
2019
Q2 | $300K | Sell |
41,850
-42,684
| -50% | -$483K | ﹤0.01% | 1785 |
|
|
2019
Q1 | $1.12M | Buy |
84,534
+56,356
| +200% | +$599K | ﹤0.01% | 1594 |
|
|
2018
Q4 | $222K | Hold |
28,178
| – | – | ﹤0.01% | 1852 |
|
|
2018
Q3 | $312K | Hold |
28,178
| – | – | ﹤0.01% | 1833 |
|
|
2018
Q2 | $378K | Buy |
+28,178
| New | +$353K | ﹤0.01% | 1585 |
|
Other funds holding CBAY
MetLife Investment Management's CBAY Position: Q1 2024 in Review
MetLife Investment Management sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 59,442 shares — an estimated $1.4M sold.
MetLife Investment Management first reported a position in CBAY in Q2 2018 and held it in 15 quarters. The position peaked at $1.4M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.
- MetLife Investment Management reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
- MetLife Investment Management sold 59,442 Cymabay Therapeutics shares in Q1 2024, an estimated $1.4M.
- MetLife Investment Management first reported a position in Cymabay Therapeutics in Q2 2018 and held it in 15 quarters.
- MetLife Investment Management's Cymabay Therapeutics position peaked at $1.4M in Q4 2023.
- 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.
Based on MetLife Investment Management's 13F filing for Q1 2024, filed 14 May 2024.